GLENMARK — Glenmark Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹397.23bn
- IN₹394.64bn
- IN₹118.13bn
Annual cashflow statement for Glenmark Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 10,961 | 13,825 | 14,412 | 8,685 | 5,692 |
| Depreciation | |||||
| Non-Cash Items | 2,191 | 2,013 | 3,004 | 8,607 | 3,790 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3,399 | -8,961 | -11,197 | -17,144 | -20,362 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 13,924 | 11,312 | 11,087 | 6,261 | -4,572 |
| Capital Expenditures | -9,324 | -7,748 | -7,901 | -6,078 | -9,149 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1,489 | 995 | 4,568 | 793 | 54,758 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -7,835 | -6,752 | -3,333 | -5,285 | 45,609 |
| Financing Cash Flow Items | -3,015 | -2,936 | -3,079 | -4,643 | -5,168 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -4,447 | -4,418 | -5,205 | -775 | -39,061 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1,740 | 278 | 2,724 | 325 | 2,152 |